BioXcel Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
BioXcel Therapeutics, Inc. (BTAI) reported Capital Expenditures Incurred but Not yet Paid of $22.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-16.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2023-03-16
- BioXcel Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2021-03-31 was $9.00K.
- BioXcel Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $22.00K, a 78.85% decline from fiscal 2020.
- BioXcel Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $104.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|
| 2021-12-31 | $22.00K 10-K · filed 2023-03-16 | |
| 2021-03-31 | $9.00K 10-Q · filed 2022-05-09 | |
| 2020-12-31 | $104.00K 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |